Table 1.

Patient and tumor baseline characteristics: High versus low chemotherapy preference

	High preference N = 68 N (%)	Low preference N = 77 N (%)	p-value
Race
White	53 (77.9)	73 (94.8)
Other	13 (19.1)	3 (3.9)	0.004
Unknown	2 (2.9)	1 (1.3)
Age,
65–69 years	29 (42.7)	29 (37.7)
70–80 years	37 (54.4)	41 (53.3)	0.31
> 80 years	2 (2.6)	7 (9.1)
Primary surgery
Less than mastectomy	29 (42.6)	43 (55.8)	0.11
Mastectomy	39 (57.4)	34 (44.2)
ER status
Negative	19 (27.9)	32 (41.6)	0.087
Positive	49 (72.1)	45 (58.4)
PR status
Negative	32 (47.1)	42 (54.6)	0.37
Positive	36 (52.9)	35 (45.4)
Performance status
0–1	67 (98.5)	75 (97.4)	0.99
2	1 (1.5)	2 (2.6)
T Stage
T1	27 (40.3)	34 (46.0)	0.71
T2	38 (56.7)	37 (50.0)
T3	2 (3.0)	3 (4.0)
N Stage
N0	25 (39.7)	31 (40.8)
N1	31 (49.2)	39 (51.3)	0.84
N2	6 (9.5)	6 (7.9)
N3	1 (1.6)	0
Number of positive nodes
0	25 (36.8)	32 (42.1)
1	15 (22.1)	18 (23.7)	0.77
2	13 (19.1)	10 (13.2)
3 or more	15 (22.1)	16 (21.0)
Treatment arm
CMF or AC	29 (42.6)	39 (50.6)	0.33
Capecitabine	39 (57.4)	38 (49.4)
Highest level of education
Grades 1–11	11 (16.4)	5 (6.8)
High school graduate	18 (26.9)	33 (44.6)	0.09
Some college	20 (29.8)	20 (27.0)
College/Advanced degree	18 (26.9)	16 (21.6)
Marital status
Separated/Divorced	6 (9.0)	4 (5.3)
Married	38 (56.7)	39 (52.0)	0.70
Single, never married	7 (10.4)	10 (13.3)
Widowed	16 (23.9)	22 (29.3)
Employment status
Employed Full/Part Time	8 (11.9)	5 (6.7)
Retired	43 (64.2)	54 (72.0)	0.47
Other	16 (23.9)	16 (21.3)

CMF: Cyclophosphamide/Methotrexate/5-Fluorouracil; AC: Doxorubicin/Cyclophosphamide